Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy

This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.

Study Overview

• Status: Completed
• Conditions: Familial Partial Lipodystrophy
• Intervention / Treatment: Drug: AKCEA-ANGPTL3-LRx

• Study Type: Interventional
• Enrollment (Actual): 4
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Michigan
    • Ann Arbor, Michigan, United States, 48105
      • Clinical Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• Must give written informed consent to participate in the study.
• Clinical diagnosis of familial partial lipodystrophy plus diagnosis of type 2 diabetes mellitus and hypertriglyceridemia.
• Diagnosis of diabetes mellitus, made at least 6 months prior to the Screening with hemoglobin A1c (HbA1c) ≥ 7% to ≤ 12% at Screening and on anti-diabetic therapy as defined in study protocol.
• Hypertriglyceridemia as defined by fasting triglycerides (TG) levels ≥ 500 milligrams per deciliter (mg/dL) at both Screening and Qualification visits. Participants with the clinical diagnosis of FPL and with fasting TG levels ≥ 200 (≥ 2.26 millimoles per liter [mmol/L]) to < 500 mg/dL (≥ 5.7 mmol/L) who meet the genetic or family history criteria for study inclusion may be further screened and enrolled in the study.
• Presence of hepatosteatosis (fatty liver), as evidenced by a Screening magnetic resonance imaging (MRI) indicating a hepatic fat fraction (HFF) ≥ 6.4%.

Key Exclusion Criteria:

• Diagnosis of generalized lipodystrophy.
• Diagnosis of acquired partial lipodystrophy (APL).
• Acute pancreatitis within 4 weeks of Screening.
• Acute coronary syndrome within 6 months of Screening.
• Major surgery within 3 months of Screening.
• Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AKCEA-ANGPTL3-LRx 20 mg; Participants received AKCEA-ANGPTL3-LRx 20 milligrams (mg) administered every week for 26 weeks by subcutaneous (SC) injection.	Drug: AKCEA-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx solution for SC injection.; Other Names: ISIS 703802

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27)	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Area Under the Curve (AUC) of Plasma Glucose as Assessed by Mixed Meal Test (MMT) at End of the Treatment	Change from Baseline to Week 27 in the area under the curve (AUC) of Plasma Glucose was assessed.	Baseline and End of the Treatment (Week 27)
Change From Baseline in AUC of Serum Insulin as Assessed by MMT at End of the Treatment	Change from Baseline to Week 27 in the AUC of Serum Insulin was assessed.	Baseline and End of the Treatment (Week 27)
Change From Baseline in AUC of Serum C-peptide as Assessed by MMT at End of the Treatment	Change from Baseline to Week 27 in the AUC of Serum C-peptide was assessed.	Baseline and End of the Treatment (Week 27)
Change From Baseline in AUC of Free Fatty Acid (FFA) as Assessed by MMT at End of the Treatment	Change from Baseline to Week 27 in the AUC of FFA was assessed.	Baseline and End of the Treatment (Week 27)
Change From Baseline in AUC of Serum Ghrelin as Assessed by MMT at End of the Treatment	Change from Baseline to Week 27 in the AUC of Serum Ghrelin was assessed.	Baseline and End of the Treatment (Week 27)
Change From Baseline in AUC of Incretin Hormone (Gastric Inhibitory Polypeptide [GIP]) as Assessed by MMT at End of the Treatment	Change from Baseline to Week 27 in the AUC of Incretin Hormone: GIP was assessed.	Baseline and End of the Treatment (Week 27)
Change From Baseline in AUC of Incretin Hormone (Glucagon-like Peptide -1 [GLP-1]) as Assessed by MMT at End of the Treatment	Change from Baseline to Week 27 in the AUC of Incretin Hormone: GLP-1 was assessed.	Baseline and End of the Treatment (Week 27)
Change From Baseline in AUC of Peptide Tyrosine Tyrosine (PYY) as Assessed by MMT at End of the Treatment	Change from Baseline to Week 27 in the AUC of PYY was assessed.	Baseline and End of the Treatment (Week 27)
Change From Baseline in HDL-C at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in LDL-C at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment. LDL-C calculated using ultracentrifugation method.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Total Cholesterol (TC) at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in VLDL-C at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment. VLDL-C was calculated using direct test method.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Non-HDL-C at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in ApoB at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in ApoB-48 at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Apolipoprotein B 100 (ApoB-100) at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in ApoA-1 at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in ApoC-III at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in ApoC-III: Chylomicron at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in ApoC-III: VLDL at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in ApoC-III: LDL at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in ApoC-III: HDL at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Lipoprotein a (Lp[a]) at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Free Fatty Acid (FFA) at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Glycerol Levels at End of the Treatment	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Lipoprotein Particle Size at End of the Treatment	The baseline was defined as the Day 1 pre-dose fasting assessment. Lipoprotein Particle size included: HDL size, LDL size and VLDL size.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Hemoglobin A1c (HbA1c) at End of the Treatment	The baseline was defined as the last non-missing assessment prior to the first dose of study drug.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Homeostasis Model Assessment-Estimated Insulin Resistance (HOMA-IR)	The baseline was defined as the average of Day 1 pre-dose fasting assessment and the last fasting measurement prior to Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Adiponectin at End of the Treatment	The baseline was defined as the Day 1 pre-dose fasting assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in and Leptin at End of the Treatment	The baseline was defined as the Day 1 pre-dose fasting assessment	Baseline and End of the Treatment (Week 27)
Change From Baseline in Hepatic Fat Fraction (HFF) as Assessed by Magnetic Resonance Imaging (MRI) at End of the Treatment	The baseline was defined as the last non-missing assessment prior to the first dose of study drug.	Baseline and End of the Treatment (Week 27)
Changes From Baseline in Body Fat Distribution for Various Areas in the Body as Measured by Skinfold Thickness at End of the Treatment	The baseline was defined as the last assessment prior to the first dose of study drug. Change in body fat distribution was measured as right anterior thigh skinfold thickness and right tricep skinfold thickness by Skinfold Thickness.	Baseline and End of the Treatment (Week 27)
Changes From Baseline in Body Fat Distribution for Various Areas in the Body as Measured by Dual-Energy X-ray Absorptiometry (DEXA) at End of the Treatment	The baseline was defined as the Screening assessment. Change in body fat distribution (arm bone mass, arm fat mass, arm lean mass, arm total mass, leg bone mass, leg fat mass, leg lean mass, leg total mass, total bone mass, total fat mass, total lean mass, total total mass , trunk bone mass, trunk fat mass, trunk lean mass and trunk total mass) was measures obtained from DEXA.	Baseline and End of the Treatment (Week 27)
Changes From Baseline in Body Fat Distribution for Total Bone Mineral Density in the Body as Measured by Dual-Energy X-ray Absorptiometry (DEXA) at End of the Treatment	The baseline was defined as Screening assessment. Change in body fat distribution for total Bone mineral density was measures obtained from DEXA.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Visceral Adipose Tissue (VAT) as Measured by Magnetic Resonance Imaging (MRI) at End of the Treatment	The baseline was defined as the last assessment prior to the first dose of study drug.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Subcutaneous Adipose Tissue (SAT) as MRI at End of the Treatment	The baseline was defined as the last assessment prior to the first dose of study drug.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Body Weight at End of the Treatment	The baseline was defined as the Day 1 pre-dose assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Waist Circumference at End of the Treatment	The baseline was defined as the Screening assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Waist/Hip Ratio at End of the Treatment	The baseline was defined as screening assessment.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Quality of Life (QoL)	The baseline was defined as the screening assessment. Quality of life measures the severity of fatigue, severity of trouble thinking or remembering and severity of waking up tired in participants, on a scale ranging from 0 to 3, where, 0= No problem, 1= Mild, 2= Moderate and 3= severe. Higher scores indicates more severity or more impact on quality of life.	Baseline and End of the Treatment (Week 27)
Change From Baseline in Pain Score at End of the Treatment	The baseline was defined as a Screening assessment. Pain score is used to determine disease activity in participants, on a scale ranging from 0 to 5 where 0= never, 1= hardly noticed, 2= slightly, 3= moderately, 4= strongly, and 5= very strongly where higher scores indicated higher degree of pain.	Baseline and End of the Treatment (Week 27)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)	An adverse event (AE) is any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. "A treatment-emergent adverse event (TEAE) is defined as any AE starting on or after the first dose of the study drug	From signing of informed consent to end of follow up period (Up to week 40)

Collaborators and Investigators

• Sponsor: Akcea Therapeutics
• Collaborators: Ionis Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): June 15, 2018
• Primary Completion (Actual): July 30, 2019
• Study Completion (Actual): August 21, 2019

Study Registration Dates

• First Submitted: April 21, 2018
• First Submitted That Met QC Criteria: April 21, 2018
• First Posted (Actual): May 2, 2018

Study Record Updates

• Last Update Posted (Actual): February 16, 2021
• Last Update Submitted That Met QC Criteria: January 27, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Keywords: Lipid Metabolism Disorders; Dyslipidemias; Lipodystrophy; Lipodystrophy, Familial Partial; Kobberling-Dunnigan syndrome (type 1 and 2); Lipoatrophic Diabetes
• Additional Relevant MeSH Terms: Metabolic Diseases; Skin Diseases; Genetic Diseases, Inborn; Lipid Metabolism Disorders; Laminopathies; Skin Diseases, Metabolic; Lipodystrophy; Lipodystrophy, Familial Partial
• Other Study ID Numbers: ISIS 703802-CS5

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No